Sparks commentary

Healthcare

Sparks

Isofol Medical (ST: ISOFOL) – first cohort complete in arfolitixorin study
Published by Arron Aatkar, PhD

Isofol Medical has announced completion of the first patient cohort in its ongoing Phase I/II trial of arfolitixorin in combination with standard 5-FU-based first-line therapy for metastatic colorectal cancer. The study aims to optimise dosing while assessing safety and pharmacokinetics, and exploring early signs of efficacy. This marks an important early milestone in re-establishing clinical momentum for arfolitixorin after prior setbacks. Following a meeting with the Safety Review Committee, the company has received recommendation to proceed to the next dose cohort.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.